The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals.

Here's where Dr. David Eifrig says to move your money immediately.

Phillip A. Sharp net worth and biography

Phillip Sharp Biography and Net Worth

Director of Alnylam Pharmaceuticals

Phillip Sharp, Ph.D., has served on our board of directors since January 2017. Dr. Sharp has been an institute professor at Massachusetts Institute of Technology, or MIT, since 1999. Prior to that, he led MIT’s Department of Biology from 1991 to 1999 before assuming the directorship of the McGovern Institute from 2000 to 2004. Much of Dr. Sharp’s scientific work has been conducted at MIT’s Center for Cancer Research (now the Koch Institute), which he joined in 1974 and directed from 1985 to 1991. Dr. Sharp is the winner of the 1993 Nobel Prize in Physiology or Medicine. Dr. Sharp is a member of the board of directors of Alnylam Pharmaceuticals, Inc. and Syros Pharmaceuticals, Inc., each a publicly traded biopharmaceutical company. From 1982 to 2009, Dr. Sharp served as a director of Biogen Inc., which he co-founded in 1978. Dr. Sharp earned his B.A. from Union College (Kentucky) and his Ph.D. in Chemistry from the University of Illinois, Champaign-Urbana. He completed his postdoctoral training at the California Institute of Technology.

What is Phillip A. Sharp's net worth?: The estimated net worth of Phillip A. Sharp is at least $38.07 million as of November 25th, 2020. Dr. Sharp owns 265,633 shares of Alnylam Pharmaceuticals stock worth more than $38,067,865 as of April 26th. This net worth evaluation does not reflect any other investments that Dr. Sharp may own. Learn More about Phillip A. Sharp's net worth.
How do I contact Phillip A. Sharp?: The corporate mailing address for Dr. Sharp and other Alnylam Pharmaceuticals executives is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. Alnylam Pharmaceuticals can also be reached via phone at (617) 551-8200 and via email at [email protected]. Learn More on Phillip A. Sharp's contact information.
Has Phillip A. Sharp been buying or selling shares of Alnylam Pharmaceuticals?: Phillip A. Sharp has not been actively trading shares of Alnylam Pharmaceuticals over the course of the past ninety days. Most recently, Phillip A. Sharp sold 30,000 shares of the business's stock in a transaction on Wednesday, November 25th. The shares were sold at an average price of $124.89, for a transaction totalling $3,746,700.00. Following the completion of the sale, the director now directly owns 265,633 shares of the company's stock, valued at $33,174,905.37. Learn More on Phillip A. Sharp's trading history.
Who are Alnylam Pharmaceuticals' active insiders?: Alnylam Pharmaceuticals' insider roster includes Michael Bonney (Director), Jeffrey Dunn (CEO), Indrani Franchini (EVP), Pushkal Garg (CMO), Yvonne Greenstreet (COO), Laurie Keating (EVP), John Maraganore (CEO), Steven Paul (Director), Jeffrey Poulton (CFO), Phillip Sharp (Director), Tolga Tanguler (EVP), and Akshay Vaishnaw (Insider). Learn More on Alnylam Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Alnylam Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 59,443 shares worth more than $11,438,789.45. The most recent insider tranaction occured on December, 27th when Director Michael W Bonney sold 30,000 shares worth more than $5,850,000.00. Insiders at Alnylam Pharmaceuticals own 1.5% of the company. Learn More about insider trades at Alnylam Pharmaceuticals.
Information on this page was last updated on 12/27/2023.

Phillip A. Sharp Insider Trading History at Alnylam Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/25/2020	Sell	30,000	$124.89	$3,746,700.00	265,633
11/18/2019	Sell	15,000	$91.71	$1,375,650.00	250,633

Phillip A. Sharp Buying and Selling Activity at Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Company Overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $143.31

$143.00

$146.07

50 Day Range

MA: $150.29

$143.71

$162.81

2 Week Range

Now: $143.31

$141.98

$218.88

Volume

479,138 shs

Average Volume

776,484 shs

Market Capitalization

$18.05 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39

Move Your Money Before May 22

From Stansberry Research | Ad